Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial...
United States Chris Mccarthy Interpace Bioscience Tom Burnell Interpace Biosciences Company Medicare
Source: marketscreener.com